Cardiovascular Safety of Incretin-Based Drugs in Type Two Diabetes Mellitus Patients
Journal: Aperito Journal Of Pharmacology And Drug Designing (Vol.1, No. 1)Publication Date: 2014-10-10
Authors : Alexander E Berezin;
Page : 1-4
Keywords : Cardiovascular risk; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 analogs; Incretin-based drugs;
Abstract
Diabetes Mellitus (DM) is a chronic metabolic disease with complicated complex pathogenesis. Frequency of newly DM arises worldwide and associated with steadily increased morbidity and mortality due to DM-related complications. The incretin-based drugs are posed as remedies modulated effects of natural incretin hormones: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic peptide) and dipeptidyl peptidase enzyme 4 (DPP4). At the beginning of the era of the incretin-based therapy the treatment of T2DM with GLP-1 analogs and DPP-4 inhibitors was introduced. In fact, incretin-based drug exposure was associated with clinically significant cardiovascular protection. However, it is not known whether all GLP-1 analogs and DPP-4 inhibitors are similar in their capacities to improve cardiovascular outcomes or not that is required a continuous studies in this direction.
Other Latest Articles
- Sustained Release Drug Delivery Systems: A Patent Overview
- Recent Advances, Patent Scenarios and Future Developments on Gastro-Retentive Drug Delivery System: A Patent Overview
- Recent Approaches and Patent Survey on Colon Targeted Drug Delivery System
- Role of Pharmacogenomics in Drug Designing
- An Unusual Case of Unilateral Cochlear Nerve Agenesis with Bilateral Lateral Semicircular Canals Aplasia
Last modified: 2018-10-05 16:38:57